The antitumor drug streptozotocin (STZ) is commonly used as a diabetogenic compound inanimal models. At relatively low doses, STZ-induced
![](/images/gifchars/beta2.gif)
cell destruction is associated with Th1-driven type 1 immune reactions, including macrophages (M
![](/images/gifchars/Phi.gif)
) and IFN-
![](/images/gifchars/gamma.gif)
-producing CD8
+ Tcells. STZ induces similar Th1-dependent effects in the popliteal lymph node assay (PLNA),and because this assay allows straightforward examination of early immunostimulatingprocesses, the PLNA was used to further examine the importance of M
![](/images/gifchars/Phi.gif)
and structuralproperties of STZ in relation to the induction of type 1 immune responses. Results show thatelimination of M
![](/images/gifchars/Phi.gif)
with clodronate-containing liposomes prior to exposure to STZ preventsthe occurrence of some (CD8
+ T cell activation, IFN-
![](/images/gifchars/gamma.gif)
production, and tissue destruction) butnot all (IgG2a formation) type 1 immune responses. It appeared that stimulation of M
![](/images/gifchars/Phi.gif)
dependson the
D-glucopyranose moiety of STZ, as well as on the intact reactive N-methyl-N-nitrosourea(MNU) moiety. However, the MNU moiety suffices to induce IgG2a formation. In addition,STZ-derived nitric oxide may have modulating effects on the elicitation of STZ-induced immuneresponses. Present results support the idea that M
![](/images/gifchars/Phi.gif)
activation is indispensable for the STZ-induced tissue destructive type 1 responses and that various STZ-induced type 1 immuneresponses are differently regulated.